An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs. The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection. Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab.

Find the CD3 antibody that fits your needs. Choose from 1 of 538 CD3 antibodies, which have been validated in experiments with 9701 publications and 3882 images featured in our data...

抗 CD3（小鼠和人）的最佳浓度范围为 1-3 µg/mL；抗 CD28（小鼠和人）的最佳浓度范围为 3-5 µg/mL。 方案提示： IL-2 会促进细胞毒性 T 细胞的生长和分化。

使用Anti-CD3 hIgG1 Antibody(CH2527)（Genomeditech/GM-33037AB） ，流式结果 吉满生物助力药物研发，紧随前沿靶点资讯，储备几百株现货细胞，覆盖GPCR、细胞因子、免疫检查点、TAA等多领域近200余个靶点。

Treatment of T cells with monoclonal anti-CD3 antibodies and anti-CD28 antibodies provide a co-stimulatory signal that engages the TCR which can be used for antigen-induced activation. Using functional antibodies, as described below, with or without growth factors is a more economical method to expand T cell populations.

抗CD3 单克隆抗体 （Anti-CD3 Monoclonal antibody），是一类 T细胞 表面CD3的抗体，他们是一类 免疫功能抑制药物。 1996年，首批获得批准的药物是 莫罗单抗-CD3，其用于治疗 移植排斥。 更新的单克隆抗体具有相同的作用机制，产品包括有 otelixizumab （英语：otelixizumab） 、 Teplizumab （英语：Teplizumab） 和 Visilizumab （英语：Visilizumab）。 这些药物用于治疗如 克罗恩病 、 溃疡性结肠炎 和 1型糖尿病 等病变情况 [1]，以及进行诱导 免疫耐受 [2][3]。

2021年6月17日 · Orthoclone OKT3 targets the CD3 molecule that is present exclusively on T cells and depletes them from the circulation, which makes the drug an effective immunomodulator.

cd3：双抗领域黄金靶点. 作为双抗研究领域开始较早的靶点方向，关于cd3的双抗研究自上世纪80年代起就已经开始并被认为是整个双抗时代的起源。经过近几十年的深入研究，cd3靶点愈加成熟，是目前全球双抗药物开发的黄金靶点。 图2.在研双抗药物靶点[1]

2025年3月29日 · To evaluate the efficacy of anti-CD3 monoclonal antibody (mAb) in patients with type 1 diabetes (T1D) and identify the influencing factors. Randomized controlled trials comparing anti-CD3 mAb with placebo or standard care in T1D participants were screened from PubMed, Embase, and Cochrane databases until 31 May 2024. Changes in area under the curve (AUC) of C-peptide, HbA1c level and daily ...